Trial Profile
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2020
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Glatiramer acetate
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ASSESS
- Sponsors Novartis; Novartis Pharmaceuticals
- 24 Aug 2020 Results published in the JAMA Neurology
- 10 May 2019 Results presented in a Novartis media release.
- 30 Apr 2019 According to a Novartis media release, full results will be presented at the American Academy of Neurology (AAN) 2019.